- Home
- OMER vs COE Comparison
OMER vs COE Comparison
Compare OMER & COE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- COE
- Stock Information
- Founded
- OMER 1994
- COE 2011
- Country
- OMER United States
- COE Singapore
- Employees
- OMER N/A
- COE N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- COE Other Consumer Services
- Sector
- OMER Health Care
- COE Real Estate
- Exchange
- OMER Nasdaq
- COE Nasdaq
- Market Cap
- OMER 188.1M
- COE 177.0M
- IPO Year
- OMER 2009
- COE 2016
- Fundamental
- Price
- OMER $3.61
- COE $28.75
- Analyst Decision
- OMER Strong Buy
- COE
- Analyst Count
- OMER 5
- COE 0
- Target Price
- OMER $18.00
- COE N/A
- AVG Volume (30 Days)
- OMER 951.8K
- COE 19.3K
- Earning Date
- OMER 08-06-2025
- COE 08-22-2025
- Dividend Yield
- OMER N/A
- COE N/A
- EPS Growth
- OMER N/A
- COE N/A
- EPS
- OMER N/A
- COE N/A
- Revenue
- OMER N/A
- COE $59,490,000.00
- Revenue This Year
- OMER N/A
- COE N/A
- Revenue Next Year
- OMER $3,446.91
- COE N/A
- P/E Ratio
- OMER N/A
- COE N/A
- Revenue Growth
- OMER N/A
- COE 91.87
- 52 Week Low
- OMER $2.95
- COE $11.84
- 52 Week High
- OMER $13.60
- COE $34.74
- Technical
- Relative Strength Index (RSI)
- OMER 52.22
- COE 51.40
- Support Level
- OMER $3.00
- COE $27.98
- Resistance Level
- OMER $3.25
- COE $30.46
- Average True Range (ATR)
- OMER 0.26
- COE 2.25
- MACD
- OMER 0.12
- COE -0.66
- Stochastic Oscillator
- OMER 61.97
- COE 21.70
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.